Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

A Case of Advanced Malignant Pleural Mesothelioma Treatment with Chemotherapy and Photodynamic Therapy

  • Ryu, Jae-Wook (Department of Thoracic and Cardiovascular Surgery, Dankook University College of Medicine) ;
  • Kim, Youn Seup (Department of Internal Medicine, Dankook University College of Medicine)
  • Received : 2014.11.16
  • Accepted : 2014.12.17
  • Published : 2015.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive, treatment-resistant, and generally fatal disease. A 68-year-old male who was diagnosed with MPM at another hospital came to our hospital with dyspnea. We advised him to take combination chemotherapy but he refused to take the treatment. That was because he had already received chemotherapy with supportive care at another hospital but his condition worsened. Thus, we recommended photodynamic therapy (PDT) to deal with the dyspnea and MPM. After PDT, the dyspnea improved and the patient then decided to take the combination chemotherapy. Our patient received chemotherapy using pemetrexed/cisplatin. Afterwards, he received a single PDT treatment and then later took chemotherapy using gemcitabine/cisplatin. The patient showed a survival time of 27 months, which is longer than median survival time in advanced MPM patients. Further research and clinical trials are needed to demonstrate any synergistic effect between the combination chemotherapy and PDT.

Keywords

References

  1. Ahmed I, Ahmed Tipu S, Ishtiaq S. Malignant mesothelioma. Pak J Med Sci 2013;29:1433-8.
  2. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management, and newer therapeutic strategies. Chest 2004;126:1318-29. https://doi.org/10.1378/chest.126.4.1318
  3. Regillo CD. Update on photodynamic therapy. Curr Opin Ophthalmol 2000;11:166-70. https://doi.org/10.1097/00055735-200006000-00002
  4. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin 2011;61:250-81. https://doi.org/10.3322/caac.20114
  5. Takita H, Mang TS, Loewen GM, Antkowiak JG, Raghavan D, Grajek JR, et al. Operation and intracavitary photodynamic therapy for malignant pleural mesothelioma: a phase II study. Ann Thorac Surg 1994;58:995-8. https://doi.org/10.1016/0003-4975(94)90443-X
  6. Rodriguez E, Baas P, Friedberg JS. Innovative therapies: photodynamic therapy. Thorac Surg Clin 2004;14:557-66. https://doi.org/10.1016/j.thorsurg.2004.06.004
  7. Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest 2001;120:1167-74. https://doi.org/10.1378/chest.120.4.1167
  8. Su S. Mesothelioma: path to multimodality treatment. Semin Thorac Cardiovasc Surg 2009;21:125-31. https://doi.org/10.1053/j.semtcvs.2009.07.006
  9. Gollnick SO, Brackett CM. Enhancement of anti-tumor immunity by photodynamic therapy. Immunol Res 2010;46:216-26. https://doi.org/10.1007/s12026-009-8119-4
  10. Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012;1:472-80.
  11. Moskal TL, Dougherty TJ, Urschel JD, Antkowiak JG, Regal AM, Driscoll DL, et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 1998;66:1128-33. https://doi.org/10.1016/S0003-4975(98)00799-1
  12. Pass HI, Temeck BK, Kranda K, Thomas G, Russo A, Smith P, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997;4:628-33. https://doi.org/10.1007/BF02303746
  13. Friedberg JS. Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:177-87. https://doi.org/10.1053/j.semtcvs.2009.07.001
  14. Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant mesothelioma. World J Surg 2001;25:210-7. https://doi.org/10.1007/s002680020021
  15. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44. https://doi.org/10.1200/JCO.2003.11.136

Cited by

  1. Mesoporous Silica Nanomaterials: Versatile Nanocarriers for Cancer Theranostics and Drug and Gene Delivery vol.11, pp.2, 2015, https://doi.org/10.3390/pharmaceutics11020077